Eli Lilly’s Zepbound discount: A genuine offer or a Big Pharma profit scheme?

Eli Lilly, the pharmaceutical giant, recently garnered attention with the announcement of a 50% discount on its weight loss drug Zepbound.

While the news initially seemed promising for consumers, a closer examination reveals that the discount may be more about boosting profits than genuinely improving accessibility for patients.

The company launched 2.5mg and 5mg vials of Zepbound at half price through its online portal, LillyDirect.

This move was celebrated by many who believed it would make the drug more accessible.

However, the reality is more complex, with several hidden details indicating that Eli Lilly’s motives might be less altruistic than they appear.

The devil is in the details

The discounted Zepbound vials come with significant caveats.

To benefit from the reduced prices, patients must pay out of pocket and administer the drug themselves using traditional syringes and needles.

In contrast, regular medication is available in the form of convenient autoinjector pens, which make self-administration much simpler.

For patients who struggle with self-injecting, the discounted vials are not a viable option, forcing them to continue purchasing the more expensive autoinjector pens. This makes the so-called discount irrelevant for a significant portion of patients.

Moreover, the discounted vials are exclusively available through LillyDirect, the company’s online telehealth platform.

This requirement poses an additional hurdle for those who are not comfortable with or have limited access to digital platforms, further limiting the discount’s reach.

In addition to the introduction of the discounted vials, Eli Lilly quietly increased the cost of the drug for some patients.

Previously, individuals without insurance coverage for Zepbound could apply for a discount on the autoinjector pens, reducing the price to $550 per month.

These patients now face a price increase, with the cost rising to $650 per month—a change that was not mentioned in the company’s 50% discount press release.

A similar strategy has been observed with Eli Lilly’s diabetes drug, Mounjaro, raising further concerns about the company’s pricing practices.

Experts have started reacting

Observers and experts have begun to voice their concerns about Eli Lilly’s pricing strategy, suggesting that the company’s primary goal is to maximize profits rather than address supply shortages or make the drug more affordable.

Benjamin Rome, an assistant professor at Harvard who specializes in drug pricing, criticized the company’s actions, stating,

Senator Bernie Sanders, Chairman of the Senate Committee on Health, also condemned the price hike, particularly for those already using Zepbound.

He noted,

Eli Lilly’s recent moves suggest a strategy focused on increasing profits by raising prices for existing customers while attracting new ones with a discounted offer.

This approach may ultimately backfire, as the company faces mounting criticism and negative publicity. As the situation unfolds, it will be interesting to see how Eli Lilly navigates the potential fallout from its pricing decisions.